Four-peptide research blend

KLOW

GHK-Cu / KPV / BPC-157 / thymosin beta-4 blend

Variable formula / not FDA-approved

An 80 mg research blend labeled as GHK-Cu 50 mg, KPV 10 mg, BPC-157 10 mg, and thymosin beta-4 10 mg. KLOW is a product formula, not one molecule or a clinically standardized medicine.

FULL RESEARCH GRAPHIC

KLOW research overview

A dedicated overview of the labeled four-peptide formula, evidence boundaries, and the 80 mg total blend.

Cybertide KLOW 80 mg research infographic listing GHK-Cu, KPV, BPC-157, and thymosin beta-4

Tap the graphic to open the full-resolution version.

CYBERTIDE // VISUAL PROFILEKLOW
PROFILE21
IDENTITYGHK-Cu / KPV / BPC-157 / thymosin beta-4 blendFour-peptide research blend

RESEARCH SIGNAL MAP

04 ACTIVE FIELDS
NODE 01Copper-peptide signaling
NODE 02Barrier and inflammatory models
NODE 03Preclinical tissue models
NODE 04Formula verification

EVIDENCE READOUT

Variable formula / not FDA-approved

Each ingredient has a different evidence base, and combining them does not prove additive benefit, compatibility, stability, or safety. Claims about the blend must not be inferred from research on one component.

BOUNDARY CHECK

CONTEXT REQUIRED

The report on file identifies all four components and measures content and chromatographic purity, but it does not report sterility, endotoxins, clinical effectiveness, or a validated human-use protocol.

RESEARCH CONTEXT • PRIMARY SOURCE LINKED • QR READYSOURCE ↗

SUBMITTED LAB DOCUMENTS

Test results

Reports may describe other strengths or blends. Match the labeled amount, composition, and exact lot to your vial. A report for another strength does not verify your vial. Each record identifies whether an exact lot was supplied.

VIAL REFERENCE

3 mL mixing math & dosing context

Every number is labeled by evidence level. The 3 mL reference calculates concentration and U-100 volume; it does not prove solvent compatibility, sterility, stability, or suitability for injection.

VIAL STRENGTH

KLOW 80 mg total blend

AFTER 3.0 mL26.67 mg/mL0.27 mg per U-100 unit

Label formula: GHK-Cu 50 mg + KPV 10 mg + BPC-157 10 mg + thymosin beta-4 10 mg. The calculator uses the labeled 80 mg formula, not the assayed content.

AMOUNTVOLUMEU-100
2 mg0.07 mL7.5 units
4 mg0.15 mL15 units
8 mg0.3 mL30 units
LIVE CALCULATOR

Change the liquid. See the amount.

U-100
CONCENTRATION26.667 mg/mL
DRAW VOLUME0.1 mL
AMOUNT IN THAT DRAW2.667 mg2666.7 mcg
COMPONENTS IN THAT DRAW — LABEL RATIO
GHK-Cu1.667 mg
KPV0.333 mg
BPC-1570.333 mg
Thymosin beta-40.333 mg

Calculation only: vial amount ÷ liquid volume × draw volume. It does not determine what dose to use or confirm product compatibility.

01 / MIXING REFERENCE

3.0 mL BAC-water workflow

  1. First confirm that bacteriostatic water and a 3.0 mL final volume are compatible with the exact product and vial capacity.
  2. Clean both vial stoppers with alcohol and allow them to dry.
  3. Add the 3.0 mL slowly down the inside wall instead of directing pressure onto the powder.
  4. Gently roll or swirl until dissolved; do not shake.
  5. Use product-specific refrigeration and discard guidance. If none exists, do not invent a beyond-use date.
NO ESTABLISHED HUMAN GUIDELINE

No controlled human dose for KLOW

No controlled human trial establishes a dose, frequency, route, cycle length, or combined protocol for this four-component formula. The calculator shows proportional vial math only.

FDA — compounding safety risks ↗

U-100 means 100 units = 1.0 mL. Any table result above 100 units exceeds one standard 1 mL U-100 syringe.

PRIMARY CONTEXTFDA — safety risks for certain compounded bulk substances
Open source ↗
NEXT INFOGRAPHICEpithalon →